Theralase Technologies Inc.TLT.V

Health Care · Pharmaceuticals, Biotechnology & Life Sciences · TSX-V · Canada · theralase.com

Theralase Technologies Inc. is a clinical-stage pharmaceutical company focused on the research, development, and commercialization of light-activated photo dynamic compounds to treat cancers, bacteria, and viruses. The company's lead program, TLD-1433, is in Phase II clinical trials for the treatment of Bacillus Calmette Guérin-unresponsive non-muscle invasive bladder cancer. It also operates a Device Division marketing super-pulsed laser technology for chronic pain conditions, based in Toronto, Ontario.

Key ratios

FCF / Sales

-261.0%TTM

2024 -323.8%2023 -384.0%2022 -454.4%

ROA

-88.5%TTM

2024 -82.2%2023 -77.2%2022 -64.7%

ROE

-269.4%TTM

2024 -214.3%2023 -182.9%2022 -128.3%

Revenue growth

1.5%TTM

2024 -3.5%2023 -6.0%2022 45.9%

Recent news

Correcting and Replacing: Theralase Releases Q2 2026 Financial Statements 2026-09-18 · Newsfile Theralase(R) Commences GLP Toxicology Analysis of Rutherrin(R) 2026-09-15 · Newsfile Theralase Releases Q2 2026 Financial Statements 2026-08-28 · Newsfile Theralase(R) Closes C$3.6 Million Brokered Financing 2026-08-24 · Newsfile Theralase® Announces $5 Million Brokered LIFE Offering 2026-08-10 · Newsfile Theralase® Grants Stock Options 2026-08-07 · Newsfile Theralase Engages Global One Media to Expand Global Investor Awareness 2026-08-04 · Newsfile Theralase Receives Receipt for C$100 Million Base Shelf Prospectus 2026-06-30 · Newsfile Theralase® Releases Q1 2026 Financial Statements 2026-05-29 · Newsfile Corp Theralase® Closes C$4.8 Million Offering 2026-05-20 · Newsfile Corp

Track TLT.V in your journal

Save it to a watchlist, run a reverse DCF, and keep your notes on the company in one place. Free to start.

Create a free account

Figures are sourced from third parties and shown for research only. They may be delayed or incomplete, and nothing on this page is investment advice or a recommendation to buy or sell. Read the full disclaimer